Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 11:00 ET | Source: Truveta

A new Truveta study offers a hopeful sign: Syphilis incidence is down for the first time in decades

BELLEVUE, WA, April 15, 2025 (GLOBE NEWSWIRE) -- A new study published in the American Journal of Preventive Medicine spotlights a pivotal shift in syphilis transmission patterns across the United...
March 04, 2025 08:00 ET | Source: Indaptus Therapeutics

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral...
January 04, 2024 08:00 ET | Source: Indaptus Therapeutics

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform...
March 01, 2022 19:30 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants

In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185...
December 01, 2021 07:00 ET | Source: SAB Biotherapeutics, Inc.

SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...